US 12,064,435 B2
Composition for treatment of muscular disorders
Yi-Rang Kim, Sejong (KR); and Jin-Woo Choi, Yongin-si (KR)
Assigned to ONCOCROSS CO., LTD., Seoul (KR)
Filed by ONCOCROSS CO., LTD., Seoul (KR)
Filed on May 13, 2022, as Appl. No. 17/744,339.
Application 17/744,339 is a continuation of application No. 16/607,266, granted, now 11,364,244, previously published as PCT/KR2019/004631, filed on Apr. 17, 2019.
Claims priority of application No. 10-2018-0047957 (KR), filed on Apr. 25, 2018.
Prior Publication US 2022/0265663 A1, Aug. 25, 2022
Int. Cl. A61K 31/522 (2006.01); A23L 33/10 (2016.01); A61K 31/197 (2006.01); A61K 31/437 (2006.01); A61K 45/06 (2006.01); A61P 21/00 (2006.01); A61P 21/04 (2006.01)
CPC A61K 31/522 (2013.01) [A61K 31/197 (2013.01); A61K 31/437 (2013.01); A61K 45/06 (2013.01)] 4 Claims
 
1. A method for promoting myoblast proliferation or differentiation of myoblast in treating a muscular disease comprising administering to a subject in need thereof at composition comprising dimenhydrinate,
wherein dimenhydrinate is represented by the following Chemical Formula 1:

OG Complex Work Unit Chemistry